[Antibody treatment in colorectal cancer--what the surgeon needs to know].

Abstract

Advances in the medical treatment of colorectal cancer patients have resulted in considerable improvements through the introduction of new cytotoxic drugs. The significant progress in molecular and tumour biology has produced a great number of targeted, tumour-specific, monoclonal antibodies that are now in various stages of clinical development. Two of these antibodies, cetuximab (Erbitux) und bevacizumab (Avastin), directed against the epidermal growth factor receptor (EGFR) and the vascular epithelial growth factor (VEGF), respectively, have recently been approved for use in metastatic colorectal cancer. The combination of well-known and newly developed cytotoxic agents with monoclonal antibodies makes the medical treatment of colorectal cancer patients considerably more complex, but also provides additional therapeutic strategies for patients in advanced stages of disease.

• Authors: A Thalheimer, B Illert, P Reimer, M Bueter, A Thiede, M Gasser, M Fein, A-M Waaga-Gasser, D Meyer
• Journal: Zentralblatt fur Chirurgie (Zentralbl Chir) Vol. 133 Issue 2 Pg. 101-6 (Apr 2008) ISSN: 0044-409X [Print] Germany
• Vernacular Title: Antikörpertherapie beim metastasierten kolorektalen Karzinom--was der Chirurg wissen sollte.
• PMID: 18415895 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antimetabolites, Antineoplastic
• Antineoplastic Agents
• Antineoplastic Agents, Phytogenic
• Phthalazines
• Pyridines
• Vascular Endothelial Growth Factor A
• Vitamin B Complex
• Bevacizumab
• vatalanib
• Epidermal Growth Factor
• Panitumumab
• Irinotecan
• ErbB Receptors
• Cetuximab
• Leucovorin
• Fluorouracil
• Camptothecin

Topics

• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antimetabolites, Antineoplastic (administration & dosage, therapeutic use)
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Agents, Phytogenic (administration & dosage, therapeutic use)
• Bevacizumab
• Camptothecin (administration & dosage, analogs & derivatives, therapeutic use)
• Cetuximab
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Colorectal Neoplasms (drug therapy, mortality)
• Drug Therapy, Combination
• Epidermal Growth Factor (antagonists & inhibitors)
• ErbB Receptors (antagonists & inhibitors)
• Fluorouracil (administration & dosage, therapeutic use)
• Humans
• Irinotecan
• Leucovorin (administration & dosage, therapeutic use)
• Neoplasm Metastasis
• Panitumumab
• Phthalazines (administration & dosage, therapeutic use)
• Pyridines (administration & dosage, therapeutic use)
• Randomized Controlled Trials as Topic
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Vitamin B Complex (administration & dosage, therapeutic use)